title: In vitro and in vivo activities of tigecycline-colistin combination therapies against carbapenem-resistant Enterobacteriaceae.
abstract: We assessed the activity of tigecycline (TGC) combined with colistin (COL) against carbapenem-resistant enterobacteria. Synergy occurred in vitro against the majority of isolates, with the exception of Serratia marcescens. In a simple animal model (Galleria mellonella), TGC-COL was superior (P < 0.01) in treating Escherichia coli, Klebsiella pneumoniae, and Enterobacter infections, including those with TGC-COL resistance. Clinical studies are needed to determine whether TGC-COL regimens may be a viable option.
authors.affiliation: Antimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, United Kingdom.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Betts
authors.affiliation: Antimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, United Kingdom Division of Infection, Barts Health NHS Trust, London, United Kingdom.
authors.forename: Lynette M
authors.initials: LM
authors.lastname: Phee
authors.affiliation: Department of Life Sciences, University of Roehampton, London, United Kingdom.
authors.forename: Michael
authors.initials: M
authors.lastname: Hornsey
authors.affiliation: Antimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, United Kingdom Antimicrobial Resistance Healthcare Associated Infections Reference Unit, Public Health England, Colindale, London, United Kingdom.
authors.forename: Neil
authors.initials: N
authors.lastname: Woodford
authors.affiliation: Antimicrobial Research Group, Blizard Institute, Queen Mary University of London, London, United Kingdom Division of Infection, Barts Health NHS Trust, London, United Kingdom d.w.wareham@qmul.ac.uk.
authors.forename: David W
authors.initials: DW
authors.lastname: Wareham
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015780:Carbapenems / Q000494:pharmacology; D003091:Colistin / Q000494:pharmacology*; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004754:Enterobacter / Q000187:drug effects; D004755:Enterobacteriaceae / Q000187:drug effects*; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D009036:Moths; D000078304:Tigecycline; D001618:beta-Lactamases / Q000235:genetics
chemical_list: D000900:Anti-Bacterial Agents; D015780:Carbapenems; D000078304:Tigecycline; D001618:beta-Lactamases; D008911:Minocycline; D003091:Colistin